Amzell to start Phase III for infantile epileptic disease treatment

Specialist development drug company Amzell B.V has concluded discussions with the FDA before initiating a phase 3 trial of its new treatment for infantile epileptic disease, AMZ002.

The phase 3 trial will compare AMZ002 to a different active treatment during a superiority study, as a placebo-controlled trial wouldn’t be ethical for this patient population. AMZ002 may be a sterile injectable hormone and would offer a purified synthetic alternative to an existing FDA-approved treatment for epileptic seizures.

Infantile epileptic disease can cause global neurodevelopmental delay, significant intellectual disability, and currently has limited treatment options and a poor prognosis. In most cases, the initial age of onset is between 3 and 12 months aged , and over 90% of cases begin before 12 months aged . Infantile epileptic disease is an orphan indication, affecting fewer than 200,000 patients within the us . the shortage of treatment options for the condition means there’s a substantial unmet need.

Dario N. Carrara PhD, chief scientific officer commented: “We are delighted to possess had such regeneration from the FDA on our proposed phase 3 trial of AMZ002, and hope to initiate the trial within the coming months. Our purified, synthetic injectable should provide a treatment option for epileptic seizures, suited to best meet the requirements of this highly vulnerable patient population.”

Following the sort B End of phase 2 meeting with the FDA Division of Neurology for AMZ002, Amzell has agreed the overall study design, dosing, primary and secondary endpoints and therefore the estimative sample size for the phase 3 trial, and has now submitted the protocol utilizing a Special Protocol Agreement.

Further details on this phase 3 trial are going to be confirmed following the FDA’s approval of Amzell’s proposed protocol.

AMZ002 is that the latest product to succeed in phase 3 from Amzell, which specialises in developing well-characterized active substances through to proof-of-concept or registration purchasable to commercial partners. Amzell’s innovative platform drug delivery technologies provide effective drug delivery, increased efficacy, and improved safety and compliance.

Amzell B.V may be a specialist, virtual development drug company which takes candidate or repurposed drugs and devices either through to proof of concept, or through to registration purchasable to commercial healthcare companies.

Be the first to comment on "Amzell to start Phase III for infantile epileptic disease treatment"

Leave a comment

Your email address will not be published.


*